Greywolf Therapeutics
Peter Joyce is an accomplished biochemist and geneticist with extensive experience in the biotechnology and pharmaceuticals sectors. Currently serving as CEO and Founder of Greywolf Therapeutics since February 2018, Peter also holds founder and advisory roles at Pathios Therapeutics and ThirtyFiveBio. Prior to these ventures, significant contributions were made at Vertex Pharmaceuticals as a Senior Research Scientist and Research Scientist II, as well as a Postdoctoral Research Fellow at the Medical Research Council, where Peter developed innovative models for ALS research and led collaborative efforts internationally. Early career experience includes serving as a Regulatory Advisor at Wyeth Pharmaceuticals. Peter holds a PhD in Biochemistry and Genetics and a BSc with first-class honours in Biochemistry, both from the University of Bristol.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.